Summary

Food Allergy Treatment Market Growth & Trends

The global food allergy treatment market size is anticipated to reach USD 11.33 billion by 2030 and is projected to grow at a CAGR of 8.27% from 2025 to 2030, according to a new report by Grand View Research, Inc. Key factors propelling the market growth includes the rising prevalence of food allergies worldwide and increasing R&D activities for novel drugs. Moreover, the adoption of new biological agents to treat food allergies and an increase in clinic visits by patients seeking therapy for food allergies are likely to drive the market growth over the forecast period.

The increase in funding for allergy treatments is driving advancements in research, development, and accessibility of innovative therapies, addressing the growing demand for more effective treatments & management strategies. This heightened financial support is propelling market growth and fueling the development of safer and more accessible solutions for those affected by this condition. In September 2022, COUR Pharmaceuticals, a clinical-stage biotechnology company, completed a USD 30 million financing round, with Alpha Wave Ventures as the lead investor. This funding will support the expansion of COUR's innovative immune-modifying nanoparticles (COUR NanoParticles or CNPs) technology platform. Furthermore, it will facilitate the progression of the company's two human proof-of-concept studies focused on treating food allergies. This significant investment highlights the potential for advancing immune system reprogramming approaches to address autoimmune disorders and food allergies.

Novel drugs such as Xolair, and PALFORZIA boost the market growth. In January 2020, the FDA's approval of PALFORZIA marked a significant milestone in Food Allergy Treatment. PALFORZIA addresses a crucial unmet medical need by providing a treatment option for peanut allergies. Prior to its approval, patients had limited choices beyond strict avoidance, and this approval introduced a potentially life-changing solution. This oral immunotherapy product is specifically indicated for mitigating allergic reactions, including anaphylaxis that might occur from accidental peanut exposure in children aged 4 to 17 years with a confirmed diagnosis of peanut allergy. The FDA's requirement for a Risk Evaluation and Mitigation Strategy (REMS) ensures the safe and controlled administration of PALFORZIA, boosting patient safety and healthcare provider confidence. PALFORZIA, used alongside a peanut-avoidant diet, is tailored to meet the needs of patients while being contraindicated in cases of uncontrolled asthma and eosinophilic esophagitis and other eosinophilic gastrointestinal diseases, further emphasizing its safety and suitability for specific patient populations.

However, Nestlé's Palforzia faced significant challenges. Despite a substantial investment of USD 2.6 billion in its development, the treatment regimen proved to be too cumbersome for many potential patients. When Palforzia entered the market in 2020, physicians were initially excited to offer it to their patients. However, the COVID-19 pandemic disrupted in-person treatment plans. As a result, doctors resorted to informing approximately 1,000 patients about the new drug as an option for postpandemic use. Surprisingly, only six individuals expressed interest in the treatment that had been heralded as an efficient solution for life-threatening peanut allergy, having received clearance from U.S. authorities. Even after three years, many physicians have not prescribed Palforzia. Across the U.S., it appears that doctors & patients are opting for the traditional approach of avoiding allergens and carrying adrenaline injections for emergencies instead. As a significant development in the market, in September 2023, Nestlé divested its Palforzia business to Stallergenes Greer, a company specifying in allergy diagnosis and treatment. This strategic move followed Nestlé's earlier announcement of a review of Palforzia, with Nestlé set to receive milestone payments and ongoing royalties as part of the agreement.

Food Allergy Treatment Market Report Highlights

• By allergen type, the peanuts segment led the market with the largest revenue share of 20.55% in 2024. Key factors propelling market growth include, rising prevalence of peanut allergies worldwide and increasing R&D activities for novel drugs. Moreover, growing adoption of new biological agents to treat allergies and an increase in clinic visits by patients seeking therapy for this allergy are likely to drive the market growth over the forecast period

• Based on drug type, the epinephrine segment led the market with the largest revenue share of 41.0% in 2024. Epinephrine is considered to be the medication of choice for treatment of allergic conditions. Owing to its use as the initial treatment of choice for emergency allergic conditions

• By route of administration, the oral segment is projected to grow at a steady CAGR over the forecast period. Oral food allergy treatment primarily employs Oral Immunotherapy (OIT), involving the gradual consumption of controlled amounts of food allergen

• By end use, the hospital pharmacies segment held the market with the largest revenue share of 55.48% in 2024. Hospital pharmacies serve as a critical distribution channel, facilitating the availability and efficient dispensation of medications and treatments essential for managing food allergies within a hospital environment

• North America dominated the market with the revenue share of 39.14% in 2024. The region held a major market share due to an increase in understanding of the high potential associated with allergy drugs

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Drug Type
1.2.2. Allergen Type
1.2.3. End Use
1.2.4. Regional scope
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Food Allergy Treatment Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing prevalence of peanut allergy
3.2.1.2. Increasing funding for novel drug discovery
3.2.1.3. Rising awareness programs
3.2.2. Market restraint analysis
3.2.2.1. High cost of treatment and products
3.3. Food Allergy Treatment Market Analysis Tools
3.3.1. Industry Analysis – Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.3.3. Pricing Analysis
Chapter 4. Food Allergy Treatment Market: Allergen Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Global Food Allergy Treatment Market by Allergen Type Outlook
4.3. Global Food Allergy Treatment Market Size & Trend Analysis, by Allergen Type, 2018 to 2030 (USD Million)
4.4. Dairy Products
4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. Poultry Product
4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.6. Tree Nuts
4.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.7. Peanuts
4.7.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.8. Shellfish
4.8.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.9. Wheat
4.9.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.10. Wheat
4.10.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.11. Soys
4.11.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.12. Other
4.12.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Food Allergy Treatment Market: Drug Type Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Global Food Allergy Treatment Market Drug Type Movement Analysis
5.3. Global Food Allergy Treatment Market Size & Trend Analysis, by Drug Type, 2018 to 2030 (USD Million)
5.4. Antihistamines
5.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.5. Epinephrine
5.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.6. Immunotherapy
5.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.6.2. Xolair
5.6.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.6.3. PALFORZIA
5.6.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.6.4. Others
5.6.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Food Allergy Treatment Market: Route of Administration Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Global Food Allergy Treatment Market Movement Analysis
6.3. Global Food Allergy Treatment Market Size & Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
6.4. Parenteral Route
6.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
6.5. Oral Route
6.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
6.6. Other
6.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 7. Food Allergy Treatment Market: End Use Estimates & Trend Analysis
7.1. Segment Dashboard
7.2. Global Food Allergy Treatment Market Movement Analysis
7.3. Global Food Allergy Treatment Market Size & Trend Analysis, by End Use 2018 to 2030 (USD Million)
7.4. Hospital Pharmacies
7.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
7.5. Retail Pharmacies
7.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
7.6. Others
7.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 8. Food Allergy Treatment Market: Regional Estimates & Trend Analysis by
8.1. Regional Market Dashboard
8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
8.3. North America
8.3.1. U.S.
8.3.1.1. Key country dynamics
8.3.1.2. Regulatory framework/ reimbursement structure
8.3.1.3. Competitive scenario
8.3.1.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
8.3.2. Canada
8.3.2.1. Key country dynamics
8.3.2.2. Regulatory framework/ reimbursement structure
8.3.2.3. Competitive scenario
8.3.2.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
8.3.3. Mexico
8.3.3.1. Key country dynamics
8.3.3.2. Regulatory framework/ reimbursement structure
8.3.3.3. Competitive scenario
8.3.3.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
8.4. Europe
8.4.1. UK
8.4.1.1. Key country dynamics
8.4.1.2. Regulatory framework/ reimbursement structure
8.4.1.3. Competitive scenario
8.4.1.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
8.4.2. Germany
8.4.2.1. Key country dynamics
8.4.2.2. Regulatory framework/ reimbursement structure
8.4.2.3. Competitive scenario
8.4.2.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
8.4.3. France
8.4.3.1. Key country dynamics
8.4.3.2. Regulatory framework/ reimbursement structure
8.4.3.3. Competitive scenario
8.4.3.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
8.4.4. Italy
8.4.4.1. Key country dynamics
8.4.4.2. Regulatory framework/ reimbursement structure
8.4.4.3. Competitive scenario
8.4.4.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
8.4.5. Spain
8.4.5.1. Key country dynamics
8.4.5.2. Regulatory framework/ reimbursement structure
8.4.5.3. Competitive scenario
8.4.5.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
8.4.6. Norway
8.4.6.1. Key country dynamics
8.4.6.2. Regulatory framework/ reimbursement structure
8.4.6.3. Competitive scenario
8.4.6.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
8.4.7. Sweden
8.4.7.1. Key country dynamics
8.4.7.2. Regulatory framework/ reimbursement structure
8.4.7.3. Competitive scenario
8.4.7.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
8.4.8. Denmark
8.4.8.1. Key country dynamics
8.4.8.2. Regulatory framework/ reimbursement structure
8.4.8.3. Competitive scenario
8.4.8.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
8.5. Asia Pacific
8.5.1. Japan
8.5.1.1. Key country dynamics
8.5.1.2. Regulatory framework/ reimbursement structure
8.5.1.3. Competitive scenario
8.5.1.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
8.5.2. China
8.5.2.1. Key country dynamics
8.5.2.2. Regulatory framework/ reimbursement structure
8.5.2.3. Competitive scenario
8.5.2.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
8.5.3. India
8.5.3.1. Key country dynamics
8.5.3.2. Regulatory framework/ reimbursement structure
8.5.3.3. Competitive scenario
8.5.3.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
8.5.4. Australia
8.5.4.1. Key country dynamics
8.5.4.2. Regulatory framework/ reimbursement structure
8.5.4.3. Competitive scenario
8.5.4.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
8.5.5. South Korea
8.5.5.1. Key country dynamics
8.5.5.2. Regulatory framework/ reimbursement structure
8.5.5.3. Competitive scenario
8.5.5.4. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
8.5.6. Thailand
8.5.6.1. Key country dynamics
8.5.6.2. Regulatory framework/ reimbursement structure
8.5.6.3. Competitive scenario
8.5.6.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
8.6. Latin America
8.6.1. Brazil
8.6.1.1. Key country dynamics
8.6.1.2. Regulatory framework/ reimbursement structure
8.6.1.3. Competitive scenario
8.6.1.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
8.6.2. Argentina
8.6.2.1. Key country dynamics
8.6.2.2. Regulatory framework/ reimbursement structure
8.6.2.3. Competitive scenario
8.6.2.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
8.7. MEA
8.7.1. South Africa
8.7.1.1. Key country dynamics
8.7.1.2. Regulatory framework/ reimbursement structure
8.7.1.3. Competitive scenario
8.7.1.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
8.7.2. Saudi Arabia
8.7.2.1. Key country dynamics
8.7.2.2. Regulatory framework/ reimbursement structure
8.7.2.3. Competitive scenario
8.7.2.4. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
8.7.3. UAE
8.7.3.1. Key country dynamics
8.7.3.2. Regulatory framework/ reimbursement structure
8.7.3.3. Competitive scenario
8.7.3.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
8.7.4. Kuwait
8.7.4.1. Key country dynamics
8.7.4.2. Regulatory framework/ reimbursement structure
8.7.4.3. Competitive scenario
8.7.4.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Recent Developments & Impact Analysis, By Key Market Participants
9.2. Company/Competition Categorization
9.3. Vendor Landscape
9.3.1. List of key distributors and channel partners
9.3.2. Key customers
9.3.3. Key company market share analysis, 2024
9.3.4. Sanofi SA
9.3.4.1. Company overview
9.3.4.2. Financial performance
9.3.4.3. Product benchmarking
9.3.4.4. Strategic initiatives
9.3.5. Stallergenes Greer
9.3.5.1. Company overview
9.3.5.2. Financial performance
9.3.5.3. Product benchmarking
9.3.5.4. Strategic initiatives
9.3.6. DBV Technologies
9.3.6.1. Company overview
9.3.6.2. Financial performance
9.3.6.3. Product benchmarking
9.3.6.4. Strategic initiatives
9.3.7. Vedanta Biosciences, Inc.
9.3.7.1. Company overview
9.3.7.2. Financial performance
9.3.7.3. Product benchmarking
9.3.7.4. Strategic initiatives
9.3.8. Alladapt Immunotherapeutics, Inc.
9.3.8.1. Company overview
9.3.8.2. Financial performance
9.3.8.3. Product benchmarking
9.3.8.4. Strategic initiatives
9.3.9. COUR Pharmaceuticals
9.3.9.1. Company overview
9.3.9.2. Financial performance
9.3.9.3. Product benchmarking
9.3.9.4. Strategic initiatives
9.3.10. Aravax
9.3.10.1. Company overview
9.3.10.2. Financial performance
9.3.10.3. Product benchmarking
9.3.10.4. Strategic initiatives
9.3.11. Prota Therapeutics Pty Ltd
9.3.11.1. Company overview
9.3.11.2. Financial performance
9.3.11.3. Product benchmarking
9.3.11.4. Strategic initiatives
9.3.12. Teva Pharmaceuticals Industries Ltd.
9.3.12.1. Company overview
9.3.12.2. Financial performance
9.3.12.3. Product benchmarking
9.3.12.4. Strategic initiatives
9.3.13. F. Hoffman-La Roche Ltd.
9.3.13.1. Company overview
9.3.13.2. Financial performance
9.3.13.3. Product benchmarking
9.3.13.4. Strategic initiatives
9.3.14. Novartis AG
9.3.14.1. Company overview
9.3.14.2. Financial performance
9.3.14.3. Product benchmarking
9.3.14.4. Strategic initiatives
Chapter 10. Conclusion